Update on active specific immunotherapy with melanoma vaccines

Journal of Surgical Oncology

Volumn 66, Issue 1, 1997, Pages 55-64

  Conforti, Arnold M ^a   Ollila, David W ^a   Kelley, Mark C ^a   Gammon, Guy ^a   Morton, Donald L ^a  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

Author keywords

Autologous allogeneic vaccines; Humoral cellular immunity; Immunomodulation antigen

Indexed keywords

BCG VACCINE; CARBOHYDRATE ANTIGEN; CYCLOSPORIN; IMMUNOSTIMULATING AGENT; MELANOMA ANTIGEN; MELANOMA VACCINE;

ANTIGEN PRESENTATION; CANCER IMMUNOTHERAPY; CELL LYSATE; CELLULAR IMMUNITY; CLINICAL TRIAL; DRUG EFFICACY; FATIGUE; GASTROINTESTINAL SYMPTOM; HUMAN; HUMORAL IMMUNITY; HYPERPYREXIA; IMMUNOMODULATION; INTRADERMAL DRUG ADMINISTRATION; MELANOMA; PRIORITY JOURNAL; REVIEW;

ADJUVANTS, IMMUNOLOGIC; ANTIGENS, NEOPLASM; CANCER VACCINES; HUMANS; IMMUNITY, CELLULAR; IMMUNOTHERAPY, ACTIVE; LYMPH NODE EXCISION; MELANOMA; NEOPLASM PROTEINS; VIRAL VACCINES;

EID: 0030823710     PISSN: 00224790     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9098(199709)66:1<55::AID-JSO12>3.0.CO;2-N     Document Type: Review

References (93)

1. Nauts HC: A review of the influence of bacterial infection and of bacterial products (Coley's toxin) on malignant tumors in man. Acta Med Scand 1953;276 Suppl: 1-103.
2. Anderson CM, Buzaid AC, Legha SS: Systemic treatments for advanced cutaneous melanoma. Oncology 1995;9:1149-1158.
3. Morton DL, Malmgren RA, Holmes EC, et al.: Demonstration of antibodies against malignant melanoma by immunofluorescence. Surgery 1968;64:233-240.
4. Morton DL, Eilber FR, Malmgren RA, et al.: Immunological factors which influence responses to immunotherapy in malignant melanoma. Surgery 1970;68:158-164.
5. Mukherji B, Chakraboity NG, Sivanandham M: T-cell clones that react against autologous human tumors. Immunol Rev 1990;116: 33-62.
6. Kan-Mitchell J, Huang XQ, Steinman L, et al.: Clonal analysis of in vivo activated CD8+ cytotoxic T lymphocytes from a melanoma patient responsive to active specific immunotherapy. Cancer Immunol Immunother 1993;37:15-25.
7. Morton DL, Wanek LA, Nizze JA, et al.: Improved long-term survival after lymphadenectomy of melanoma metastatic to regional nodes. Ann Surg 1991;214:491-501.
8. Kelly JW, Sagebeil RW, Blois MS: Regression in malignant melanoma: A histological feature without independent prognostic significance. Cancer 1985;56:2287-2291.
9. Trau H, Kopf AW, Riegel DS, et al.: Regression in malignant melanoma. J Am Acad Dermatol 1983;8:363-368.
10. McGovern VJ, Shaw HM, Milton GW: Prognosis in patients with thin malignant melanoma: influence of regression. Histopathology 1983;7:673-680.
11. Day CL, Mihm MC, Sober AJ, et al.: Level IV lesions. Prognostic factors for melanoma patients with lesions 0.76-1.69 mm in thickness: An appraisal of "thin" level IV lesions. Ann Surg 1982; 195:30-34.
12. Gutterman JU, McBridge C, Freireich EJ, et al.: Active immunotherapy with BCG for recurrent malignant melanoma. Lancet 1973;1:1208-1212.
13. Czarnetzki BM, Macher E, Suciu S, et al.: Long-term adjuvant immunotherapy in stage I high risk malignant melanoma, comparing two BCG preparations versus non-treatment in a randomised multicentre study (EORTC Protocol 18781). Eur J Cancer 1993;29A:1237-1242.
14. Linehan DC, Goedegebuure PS, Eberlein TJ: Vaccine therapy for cancer. Ann Surg Oncol 1996;3:219-228.
15. Kawakami Y, Eliyahu S, Delgado CH, et al.: Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci USA 1994;91:6458-6462.
16. Irie RF, Morton DL: Regression of cutaneous metastatic melanoma by intralesional injection with human monoclonal antibody to ganglioside GD2. Proc Natl Acad Sci USA 1986;83:8694-8698.
17. Oldham RK, Foon KA, Morgan AC, et al.: Monoclonal antibody therapy of malignant melanoma: In vivo localization in cutaneous metastasis after intravenous administration. J Clin Oncol 1984;2: 1235-1244.
18. Morton DL, Barth A: Vaccine therapy for malignant melanoma. CA Cancer J Clin 1996;46:225-244.
19. Ravindranath MH, Morton DL: Active specific immunotherapy with vaccines. In Holland JF, Frei E, Bast R, et al. (eds): "Cancer Medicine," 4th ed. Baltimore: Williams & Wilkins, 1997, p1179-1198.
20. Brichard V, Van Pel A, Wolfel T, et al.: The tyrosinase gene encodes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1993;178:489-495.
21. Kawakami Y, Eliyahu S, Delgado CH, et al.: Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci USA 1994;91:3515-3519.
22. Kwon BS: Pigmentation genes: The tyrosinase gene family and the p-mel 17 gene family. J Invest Dermatol 1993;100(2 Suppl): 134S-140S.
23. Adema GJ, de Boer AJ, Vogel AM, et al.: Molecular characterization of melanocyte lineage-specific antigen gp100. J Biol Chem 1994;269:20126-20133.
24. Vijayasaradhi S, Bouchard B, Houghton AN: The melanoma antigen gp75 is the human homologue of the mouse b (brown) locus gene product. J Exp Med 1990;171:1375-1380.
25. Orlow SJ, Boissy RE, Moran DJ, et al: Subcellular distribution of tyrosinase and tyrosinase-related protein-1: Implications for melanosomal biogenesis. J Invest Dermatol 1993;100:55-64.
26. van der Bruggen P, Traversari C, Chomez P, et al.: A gene encoding an antigen recognized by cytolytic T-lymphocytes on a human melanoma. Science 1991;254:1643-1647.
27. Traversari C, van der Bruggen P, Luescher IF, et al.: A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J Exp Med 1992;176:1453-1457.
28. Gaugler B, Van den Eynde B, van der Bruggen P, et al.: Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med 1994;179:921-930.
29. Boel P, Wildmann C, Sensi ML, et al.: BAGE: A new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity 1995;2:167-175.
30. Mittelman A, Chen ZJ, Yang H, et al.: Human high molecular weight melanoma-associated antigen (HMW-MAA) mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: Induction of humoral anti-HMW-MAA immunity and prolongation of survival in patients with stage IV melanoma. Proc Natl Acad Sci USA 1992;89:466-470.
31. Euhus DM, Gupta RK, Morton DL: Induction of antibodies to a tumor-associated antigen by immunization with a whole melanoma cell vaccine. Cancer Immunol Immunother 1989;29:247-254.
32. Stretch JR, Gatler KC, Ralfkier E, et al.: Expression of mutant p53 in melanoma. Cancer Res 1991;253:49-53.
33. Rely veld EH, Ben-Efraim S: Preparation of vaccines by the action of glutaraldehyde on toxins, bacteria, viruses, allergens and cells. Methods Enzymol 1983;93:24-60.
34. Seigler HF, Cox E, Mutzner F: Specific active immunotherapy for melanoma. Ann Surg 1978;100:366-372.
35. Tao MH, Levy R: Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma. Nature 1993;362:755-758.
36. Mitchell MS, Harel W, Kan-Mitchell J, et al.: Active specific immunotherapy of melanoma with allogeneic cell lysates: Rationale, results and possible mechanisms of action. Ann NY Acad Sci 1993;690:153-165.
37. Morton DL, Foshag LJ, Hoon DS, et al.: Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann Surg 1992;216:463-482.
38. Berd D, Mastrangelo MJ: Active immunotherapy of human melanoma exploiting the immunopotentiating effects of cyclophosphamide. Cancer Invest 1988;6:337-349.
39. McAdam A, Pulaski B, Harkins S, et al.: Coexpression of IL-2 and gamma-IFN enhances tumor immunity. Ann NY Acad Sci 1993; 690:349-351.
40. Peters LC, Brandhorst JS, Hanna MG Jr: Preparation of immunotherapeutic autologous tumor cell vaccines from solid tumors. Cancer Res 1979;39:1353-1360.
41. Berd D, MacGuire HC, McCue P, et al.: Treatment of metastatic melanoma with an autologous tumor-cell vaccine: Clinical and immunologic results in 64 patients. J Clin Oncol 1990;8:1858-1867.
42. Stingl G, Brocker EB, Mertelsmann R, et al.: Phase I study to the immunotherapy of metastatic malignant melanoma by a cancer vaccine consisting of autologous cancer cells transfected with the human IL-2 gene. Hum Gene Ther 1996;7:551-563.
43. Cascinelli N, Foa R, Parmiani G, et al.: Active immunization of metastatic melanoma patients with interleukin-4 transduced, allogeneic melanoma cells: A phase I-II study. Hum Gene Ther 1994; 5:1059-1064.
44. Morton DL, Nizze A, Hoon D, et al.: Improved survival of advanced stage IV melanoma following active immunotherapy: Correlation with immune response to melanoma vaccine. Proc Am Soc Clin Oncol 1993;12:391.
45. Austin FC, Boon CW: Virus augmentation of the antigenicity of tumor cell extracts. Adv Cancer Res 1979;30:301-345.
46. Wallack MK: Specific immunotherapy with vaccinia oncolysates. Cancer Immunol Immunother 1981;12:1-4.
47. Wallack MK, Bash JA, Leftheriotis E, et al.: Positive relationship of clinical and serologic responses to vaccinia melanoma oncolysate. Arch Surg 1987;122:1460-1463.
48. Wallack MK, Sivanandham M, Balch CM, et al.: A phase III randomized double-blind, multiinstitutional trial of vaccinia melanoma oncolysate-active specific immunotherapy for patients with stage II melanoma. Cancer 1995;75:34-42.
49. Hersey P: Evaluation of vaccinia viral lysates as therapeutic vaccines in the treatment of melanoma. Ann NY Acad Sci 1993;690: 167-177.
50. Hersey P: Active immunotherapy with viral lysates of micrometastases following surgical removal of high-risk melanoma. World J Surg 1992;16:251-260.
51. Mitchell MS, Harel W, Kempf RA, et al.: Active specific immunotherapy of melanoma. J Clin Oncol 1992;10:1158-1164.
52. Mitchell MS, Kan-Mitchell J, Kempf RA, et al.: Active specific immunotherapy for melanoma: Phase I trial of allogeneic lysates and a novel adjuvant. Cancer Res 1988;48:5883-5893.
53. Mitchell MS, Harel W, Kan-Mitchell J, et al.: Active specific immunotherapy of melanoma with allogeneic cell lysates: Rationale, results, and possible mechanisms of action. Ann NY Acad Sci 1993;690:153-166.
54. Elliott GT, McLeod RA, Perez J, Von Eschen KB: Interim results of a phase II multicenter clinical trial evaluating the activity of a therapeutic allogeneic melanoma vaccine (Theraccine) in the treatment of disseminated malignant melanoma. Semin Surg Oncol 1993;9:264-272.
55. Mitchell MS, Jakowatz J, Harel W, et al.: Increased effectiveness of interferon alfa-2b following active specific immunotherapy for melanoma. J Clin Oncol 1994;12:402-411.
56. Mitchell MS, Rechtman DJ, Von Eschen KB: A randomized phase III trial of Melacine versus combination chemotherapy in patients with disseminated melanoma. Can J Infect Dis 1995;6(C Suppl): 347C.
57. Livingston PO, Ritter G, Srivastava P, et al.: Characterization of IgG and IgM antibodies induced in melanoma patients by immunization with purified GM2 ganglioside. Cancer Res 1989;49: 7045-7050.
58. Livingston PO, Natoli EJ, Calves MJ, et al.: Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients. Proc Natl Acad Sci USA 1987;84:2911-2915.
59. Livingston PO, Wong GYC, Adluris S, et al.: Improved survival in stage III melanoma patients with GM2 antibodies: A randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol 1994;12:1036-1044.
60. Kitamura K, Livingston PO, Fortunato SR, et al.: Serological response patterns of melanoma patients immunized with a GM2 ganglioside conjugate vaccine. Proc Natl Acad Sci USA 1995;92: 2805-2809.
61. Bystryn JC: Clinical activity of a polyvalent melanoma antigen vaccine: Recent results. Cancer Res 1995;139:337-348.
62. Hoon DS, Yuzuki D, Hayashida M, et al.: Melanoma patients immunized with melanoma cell vaccine induce antibody responses to recombinant MAGE-I antigen. J Immunol 1995;154: 730-737.
63. Morioka N, Kikumoto Y, Hoon DSB, et al.: A decapeptide (Gln-Asp-Leu-Thr-Met-Lys-Tyr-Gln-Ile-Phe) from human melanoma is recognized by CTL in melanoma patients. J Immunol 1994; 153:5650-5658.
64. Morioka N, Kikumoto Y, Hoon DSB, et al.: Cytotoxic T cell recognition of a human melanoma-derived peptide with a carboxyl terminal alanine-proline sequence. Mol Immunol 1995;32: 573-581.
65. Tai T, Paulson JC, Cahan CD, et al.: Ganglioside GM2 as a human tumor antigen (OFA-1-1). Proc Natl Acad Sci USA 1983;80: 5392-5396.
66. Cahan LD, Irie RF, Singh R, et al.: Identification of a human neuroectodermal tumor antigen (OFA-I-2) as ganglioside GD2. Proc Natl Acad Sci USA 1982;79:7629-7633.
67. Tsuchida T, Saxton RE, Morton DL, et al.: Gangliosides of human melanoma. J Natl Cancer Inst 1987;78:45-54.
68. Ravindranath MH, Morton DL, Irie RF: An epitope common to gangliosides O-acetyl-GD3 and GD3 recognized by antibodies in melanoma patients after active specific immunotherapy. Cancer Res 1989;49:3891-3897.
69. Yamamoto S, Yamamoto T, Saxton RE, et al.: Anti-idiotype monoclonal antibody carrying the internal image of ganglioside GM3. J Natl Cancer Inst 1990;82:1757-1760.
70. a are differentiation antigens immunogenic in human melanoma. Cancer 1997;79:1686-1697.
71. Jones RC, Kelley MC, Gupta RK, et al.: Immune response to polyvalent melanoma cell vaccine in AJCC stage III melanoma: an immunologic survival model. Ann Surg Oncol 1996;3:437-445.
72. Gabrilovich DI, Ciernik IF, Carbone DP: Dendritic cells in anti-tumor immune responses. I: Defective antigen presentation in tumor-bearing hosts. Cell Immunol 1996;170:101-110.
73. Hoon DSB, Banez M, Okun E, et al.: Modulation of human melanoma cells by interleukin-4 and in combination with γ-interferon and α-tumor necrosis factor. Cancer Res 1991;51:2002-2008.
74. Rosenberg SA, Packard BS, Aebersold PM, et al.: Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. N Engl J Med 1988;319: 1676-1680.
75. Golumbek PT, Azhari R, Jaffee EM: Controlled release, biodegradable cytokine depots: A new approach in cancer vaccine design. Cancer Res 1993;53:5841-5844.
76. Zatloukal K, Schneeberger A, Berger M, et al.: Elicitation of a systemic and protective anti-melanoma immune response by an IL-2-based vaccine. J Immunol 1995;154:3406-3419.
77. Porgador A, Gansbacher B, Bannerji R, et al.: Anti-metastatic vaccination of tumor-bearing mice with IL-2-gene-inserted tumor cells. Int J Cancer 1993;53:471-477.
78. Moller AR, McBride WH, Dubinett SM, et al.: Transduction of human melanoma cell lines with human interleukin-7 gene using retroviral-mediated gene transfer: Comparison of immunologic properties with interleukin-2. Blood 1993;82:3686-3694.
79. Dranoff G, Jaffee E, Lazenby A, et al.: Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993;90: 3539-3543.
80. Wakimoto H, Abe J, Tsunoda R, et al.: Intensified antitumor immunity by a cancer vaccine that produces granulocyte-macrophage colony-stimulating factor plus interleukin 4. Cancer Res 1996;56:1828-1833.
81. Cascinelli N, Foa R, Paramani G: Active immunization of metastatic melanoma patients with interleukin-4 transduced allogeneic melanoma cells: A phase I-II study. Human Gene Ther 1994;5: 1059-1064.
82. Osanto S, Brouwenstjin N, Vaessen N, et al.: Gene therapy of metastatic melanoma patients with IL-2 transfected melanoma cells. Proc Am Soc Clin Oncol 1994;13:293.
83. Rankin EM, Spits H, Orsini D, et al.: A phase I study of vaccination with autologous, GM-CSF transduced and irradiated cells in patients with advanced melanoma. Proc Am Soc Clin Oncol 1995;14:226.
84. Steinman RM: Dendritic cells and immune-based therapies. Exp Hematol 1996;24:859-862.
85. Tahara H, Zeh HJ, Storkus WJ, et al.: Fibroblasts genetically engineered to secrete interleukin-12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. Cancer Res 1994;54:182-189.
86. Romani N, Reider D, Heuer M, et al.: Generation of mature dendritic cells from human blood: An improved method with special regard to clinical applicability. J Immunol Methods 1996;196: 137-151.
87. Porgador A, Snyder D, Gilboa E: Induction of antitumor immunity using bone marrow generated dendritic cells. J Immunol 1996; 156:2918-2926.
88. Celluzzi CM, Mayordomo JI, Storkus WJ, et al.: Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J Exp Med 1996;183:7-11.
89. Gabrilovich DI, Nadaf S, Corak J, et al.: Dendritic cells in anti-tumor immune responses. II: Dendritic cells grown from bone marrow precursors but not mature DC from tumor-bearing mice are effective antigen carriers in the therapy of established tumors. Cell Immunol 1996;170:111-119.
90. Mukherji B, Chakraborty NG, Yamasaki S, et al.: Induction of antigen-specific cytolytic T-cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells. Proc Natl Acad Sci USA 1995;92:8078-8082.
91. Hu X, Chakraborty NG, Sporn JS, et al.: Enhancement of cytolytic T lymphocyte precursor frequency in melanoma patients following immunization with the MAGE-I peptide loaded antigen presenting cell-based vaccine. Cancer Res 1996;56:2479-2483.
92. Plaskin D, Porgador A, Vadai E, et al.: Effective anti-metastatic melanoma vaccination with tumor cells transfected with MHC genes and/or infected with Newcastle disease virus (NDV). Int J Cancer 1994;59:796-801.
93. Townsend SE, Su FW, Atherton JM, et al.: Specificity and longevity of antitumor immune responses induced by B7-transfected tumors. Cancer Res 1994;54:6477-6483.